收藏切换
On the molecular drug design from viewpoint of precision medicine
收藏切换
PDF
Zong-ru GUO*
Acta Pharmaceutica Sinica | 2017, 52(1) : 71 - 79
Less
收藏切换
Acta Pharmaceutica Sinica | 2017, 52(1): 71-79
PROFESSIONALS FORUM
On the molecular drug design from viewpoint of precision medicine
Full
Zong-ru GUO*
Affiliations
  • Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Published: 2017-01-12 doi: 10.16438/j.0513-4870.2016-0830
Outline
收藏切换

Precision medicine (PM) involves the application of "omics" analysis and system biology to analyze the cause of disease at the molecular level for targeted treatments of individual patient. Based on the targeted treatment PM is closely related to pharmaceuticals, which, as a therapeutic means and supply front, mainly embody the two aspects:drug discovery/development, and clinical administration. Innovation of new molecular entities with safety and specific efficacy is the prerequisite and guarantee for the PM practice; on the other hand, the outcome and clues in clinical PM feedback to new drug research. PM and drug research/application are interdependent and promote each other. Aimed at precision medicine, drug discovery and development involve well-known contents:the discovery and validation of targets, the association between target functions and indications (proof of concept), lead discovery and optimization, the association between preclinical investigations and clinical trials, the lean of industrialization and pharmacoeconomics. At the molecular level the therapeutic efficacy originates from the interactive binding between specific atoms or groups of the drug molecule and the complementary atoms or groups of the macromolecular target in three-dimensional space. The strict arrangement of such critical atoms, groups, or fragments reflect specific features for a precise binding to the corresponding target. An alteration of amino acid residues in mutational targets leads to the change in conformation of the target protein, and an accurate structure of drug is necessary for binding to the mutant species and avoiding off-targeting effect. For the tailoring of clinical treatment to the individual patient design and development of various new molecular entities are critical for treatment choice according to the molecular features of biological markers of patients. This article provides some examples and methods of drug design and development in the new period.

precision medicine  /  drug design  /  proof of concept  /  microscopic structure  /  binding kinetics
Zong-ru GUO. On the molecular drug design from viewpoint of precision medicine[J]. Acta Pharmaceutica Sinica, 2017 , 52 (1) : 71 -79 . DOI: 10.16438/j.0513-4870.2016-0830
Year 2017 volume 52 Issue 1
PDF
163
61
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2016-0830
  • Receive Date:2016-08-23
  • Online Date:2026-01-14
  • Published:2017-01-12
Article Data
Affiliations
History
  • Received:2016-08-23
  • Revised:2016-09-18
Affiliations
    Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2016-0830
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT